Aurora Kinase B

An aurora kinase that is a component of the chromosomal passenger protein complex and is involved in the regulation of MITOSIS. It mediates proper CHROMOSOME SEGREGATION and contractile ring function during CYTOKINESIS.

Also Known As:

Networked: 251 relevant articles (9 outcomes, 36 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Odedra, Rajesh: 5 articles (01/2017 - 06/2007)
2.	Arii, Shigeki: 4 articles (09/2015 - 01/2010)
3.	Tanaka, Shinji: 4 articles (09/2015 - 01/2010)
4.	Huang, Qiang: 4 articles (01/2015 - 08/2012)
5.	Lang, Qingyu: 4 articles (01/2015 - 08/2012)
6.	Yu, Long: 4 articles (01/2015 - 08/2012)
7.	Zhang, Haoxing: 4 articles (01/2015 - 08/2012)
8.	Crafter, Claire: 4 articles (10/2012 - 09/2006)
9.	Wilkinson, Robert W: 4 articles (10/2012 - 06/2007)
10.	Yang, Dun: 3 articles (03/2022 - 08/2010)

Related Diseases

1.	Neoplasms (Cancer) 01/01/2020 - "However, further studies in this direction should shed more light on the intracellular mechanisms involved in the regulation of Aurora kinase-B and CDK1 axis in MDM2 positive cancers." 08/01/2016 - "This phase I study investigated the maximum tolerated dose (MTD), safety, pharmacokinetics, pharmacodynamics, and antitumor activity of the Aurora B kinase inhibitor BI 811283 in patients with advanced solid tumors. " 08/01/2016 - "A phase I study of BI 811283, an Aurora B kinase inhibitor, in patients with advanced solid tumors." 04/01/2015 - "A phase 1 dose escalation study of BI 831266, an inhibitor of Aurora kinase B, in patients with advanced solid tumors." 12/01/2023 - "However, cells undergoing a prolonged mitotic arrest are prone to lose the T-loop, resulting in Aurora B kinase-dependent mitotic telomere deprotection, which was proposed as an anti-tumor mechanism that eliminates precancerous cells from the population. "
2.	Glioblastoma (Glioblastoma Multiforme) 03/06/2023 - "Here, we tested the combination of TTFields with AZD1152, an Aurora B kinase inhibitor, in primary cultures of newly diagnosed (ndGBM) and recurrent glioblastoma (rGBM). " 11/01/2019 - "Targeting Aurora kinase B attenuates chemoresistance in glioblastoma via a synergistic manner with temozolomide." 03/06/2023 - "Aurora B Kinase Inhibition by AZD1152 Concomitant with Tumor Treating Fields Is Effective in the Treatment of Cultures from Primary and Recurrent Glioblastomas." 11/01/2019 - "In this study, we investigate the underlying mechanism by which glioblastoma (GBM) cells acquire resistance to Temozolomide (TMZ) through Aurora kinase B (AURKB) thus to identify novel therapeutic targets and prognostic biomarkers for GBM. " 11/04/2005 - "Here, we found that survivin, a member of the apoptosis-inhibiting gene family, and aurora B kinase, a chromosomal passenger protein, were co-overexpressed in the various glioblastoma cell lines and tumors. "
3.	Acute Myeloid Leukemia (Acute Myelogenous Leukemia) 03/01/2010 - "In this study, we report the effects of AZD1152-HQPA, a highly selective inhibitor of aurora-B kinase, in acute myeloid leukemia (AML) cell lines and primary samples. " 03/01/2010 - "The FLT3 internal tandem duplication mutation is a secondary target of the aurora B kinase inhibitor AZD1152-HQPA in acute myelogenous leukemia cells." 01/01/2010 - "p53 is critical for the Aurora B kinase inhibitor-mediated apoptosis in acute myelogenous leukemia cells." 10/01/2011 - "A Phase I study to assess the safety, pharmacokinetics and efficacy of barasertib (AZD1152), an Aurora B kinase inhibitor, in Japanese patients with advanced acute myeloid leukemia." 09/01/2012 - "Phase I study of the Aurora B kinase inhibitor barasertib (AZD1152) to assess the pharmacokinetics, metabolism and excretion in patients with acute myeloid leukemia."
4.	Hepatocellular Carcinoma (Hepatoma) 11/01/2022 - "High expression of aurora kinase B predicts poor prognosis in hepatocellular carcinoma after curative surgery and its effects on the tumor microenvironment." 08/01/2015 - "We previously identified Aurora B kinase as the only independent factor predictive of the aggressive recurrence of hepatocellular carcinoma (HCC). " 07/01/2010 - "Using genome-wide gene expression and network analysis, we have identified "Aurora kinase B" as a unique molecule to predict the lethal recurrence of hepatocellular carcinoma (HCC) even after curative hepatectomy. " 05/01/2008 - "Aurora kinase B is a predictive factor for the aggressive recurrence of hepatocellular carcinoma after curative hepatectomy." 01/01/2010 - "The selective Aurora B kinase inhibitor AZD1152 as a novel treatment for hepatocellular carcinoma."
5.	Neuroblastoma 11/03/2015 - "Therefore, aurora B kinase inhibition is highly effective in aggressive neuroblastoma and warrants further investigation in clinical trials. " 11/03/2015 - "Aurora B kinase is a potent and selective target in MYCN-driven neuroblastoma." 09/01/2015 - "High proliferation index, as determined by immunohistochemical expression of Aurora kinase B and geminin, indicates poor prognosis in neuroblastomas." 09/01/2015 - "We investigated the impact of the biomarkers of S-G2-M phases of cell cycle, Aurora kinase B (AURKB) and geminin (GMNN), on disease progression in neuroblastomas. " 01/01/2014 - "Here, we studied the effects of the pan-aurora kinase inhibitor tozasertib (VX680, MK-0457) and the aurora kinase inhibitor alisertib (MLN8237) that shows some specificity for aurora kinase A over aurora kinase B in a panel of neuroblastoma cell lines with acquired drug resistance. "

Related Drugs and Biologics

1.	2- ((3- ((4- ((5- (2- ((3- fluorophenyl)amino)- 2- oxoethyl)- 1H- pyrazol- 3- yl)amino)quinazolin- 7- yl)oxy)propyl)(ethyl)amino)ethyl dihydrogen phosphate
2.	Small Interfering RNA (siRNA)
3.	Temozolomide (Temodar)
4.	Proteins (Proteins, Gene)
5.	Tumor Suppressor Protein p53
6.	Tamoxifen
7.	Lactoferrin
8.	Aurora Kinase A
9.	Histones (Histone)
10.	N- (4- ((3- (2- amino- 4- pyrimidinyl)- 2- pyridinyl)oxy)phenyl)- 4- (4- methyl- 2- thienyl)- 1- phthalazinamine

Related Therapies and Procedures

1.	Therapeutics
2.	Drug Therapy (Chemotherapy)
3.	Hepatectomy
4.	Aftercare (After-Treatment)